Peptonic Medical reported sales of SEK 3.1 million in the first quarter (3.8). Gross profit amounted to SEK 2.1 million (2.2), corresponding to a gross margin of 68 percent (58). The company says the improvement is mainly explained by a changed product mix and implemented structural changes in the group. Operating profit improved to SEK -5.3 million (-7.5). Operating expenses decreased by 22 percent to SEK -8.7 million (-11.2). Personnel costs fell to SEK -1.0 million (-3.0) as a result of fewer employees after the reconstruction process. The company highlights the launch of two new products within VagiVital after the end of the quarter as well as continued investment in brand building and international expansion. At the same time, the Norwegian consumer market is described as having developed strongly during the period. During the quarter, Peptonic carried out share issues totaling approximately SEK 18.2 million before issue costs as part of the reconstruction plan. The reconstruction was formally completed in December last year. Interim CEO Daniel Rudeklint says that the company is now more cost-efficient and better positioned for sustainable growth and improved profitability going forward. Peptonic Medical, SEK millionQ1 2026Q1 2025ChangeRevenue3.13.8-17%Operating profit-5.3-7.529%Net profit-5.7-7.524%